Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric
Executive Summary
House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.
You may also be interested in...
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Unless Republicans are convinced the market can't fix the problem, Mylan officials may only get congressional letters on the EpiPen price increase.
Why Generic EpiPen Is Not The Answer – Until FDA Says It Is
There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.